Journal of Young Pharmacists logo
Submit
Journal of Young PharmacistsACADEMIC PUBLISHING
Article

Effect of Caralluma fimbriata Hydroalcoholic Extraction on Olanzapine-Induced Hyperphagia and Metabolic Changes in Rats

1★, 1, 1, 1, 1, 2★ Corresponding author

  1. 1Department of Pharmacology, Pravara Rural College of Pharmacy, Pravaranagar, MaharashtraINDIA.
  2. 2Department of Pharmaceutics, Institute of Pharmacy, Loni, MaharashtraINDIA.

CORRESPONDENCE

Dighe Santosh Bhausaheb

Department of Pharmacology, Pravara Rural College of Pharmacy, Pravaranagar, MaharashtraINDIA.

santosh.dighe@pravara.in

Received: 03-07-2025; Revised: 29-08-2025; Accepted: 13-10-2025.

Volume 17, Issue 4 · pp. 914-921 · 2025 · DOI: 10.5530/jyp.20250150

ABSTRACT

Background: Olanzapine an atypical antipsychotic, is known to cause metabolic side effects such as weight gain, hyperlipidemia and oxidative stress, contributing to the development of metabolic syndrome. Caralluma fimbriata a traditional plant has shown potential in regulating weight and improving lipid metabolism. This study aims to evaluate the effects of Caralluma fimbriata hydro-alcoholic extract (CFE) on metabolic changes induced by olanzapine in rats.Materials and Methods: Thirty female Sprague-Dawley rats (180-190g) the rats were maintained under controlled environmental conditions (22±2ºC, 12 hr light/dark cycle) with free access to standard diet and water. Following a one-week acclimatization period, they were randomly divided into five experimental groups Normal (vehicle), Olanzapine (OLZ 2 mg/kg/day), OLZ+Caralluma fimbriata 100 mg/kg (CFE100+OLZ), OLZ+CFE 200 mg/kg (CFE200+OLZ), and OLZ + CFE 400 mg/kg (CFE400+OLZ). Treatments were administered orally for 21 days. Daily body weight and food intake were recorded. Blood was collected for lipid profile analysis. Upon sacrifice, organ weights and oxidative stress markers were assessed.Results: Co-administration of CFE with Olanzapine (OLZ) resulted in a significant reduction in OLZ-induced weight gain and hyperphagia. CFE also demonstrated positive effects on the metabolic changes, improving body weight gain compared to OLZ-only treated rats. Furthermore, CFE notably improved the lipid profile, demonstrating significant antihyperlipidemic effects.Conclusion: The hydro-alcoholic extract of Caralluma fimbriata effectively mitigates olanzapine-induced weight gain, oxidative stress and disturbances in lipid metabolism indicating its potential as an adjunctive therapy for managing olanzapine-induced metabolic side effects.

KEYWORDS

0% READ

FULL TEXT

INTRODUCTION

Olanzapine, a second-generation antipsychotic that was approved by the FDA in 1996 for the treatment of schizophrenia has been available in generic form since 2011. Additionally it is utilized as a long-acting injectable for schizophrenia and in conjunction with fluoxetine to treat treatment-resistant depression and bipolar depression (Thomas et al., 2023, Leucht et al., 2009, Meftah A et al., 2020). Olanzapine, however, has serious side effects, especially weight gain (Svensson et al., 2029, Lin et al., 2018) and a higher risk of metabolic syndrome which includes diabetes, insulin resistance and dyslipidemia (Hardy et al., 2011, Lanktree et al., 2018). Several strategies have been investigated to treat olanzapine-induced weight gain, including mixing olanzapine with betahistine, metformin and curcumin, zingiber officinale (Deng et al., 2012, Parasuraman et al., 2017, Ullagaddi et al., 2021). Despite these attempts weight gain remains a polygenic condition involving several proteins that contribute to metabolic syndrome and obesity. There is still a need for therapeutic approaches that can reduce these adverse effects without compromising olanzapine's therapeutic benefits. Caralluma fimbriata a succulent plant native to India, North Africa and the Middle East, is traditionally used for its appetite-suppressing properties. It has been valued for enhancing endurance and reducing hunger during scarcity. Modern research supports its role in weight management by modulating hunger-regulating neurotransmitters and metabolic pathways. Phytoconstituents like pregnane glycosides, flavonoids and saponins contribute to its effects. Clinical studies suggest it may reduce food intake and body weight but caution is advised for pregnant, breastfeeding women and those with pre-existing health conditions. Ongoing research explores its therapeutic potential (Kamalakkannan et al., 2010, Gujjala et al., 2017, Sudhakara et al., 2014).

The effects of a Caralluma fimbriata extract of on weight growth, food intake, lipid profile, oxidative stress markers and organ weight will be examined in a model of olanzapine-induced weight gain using female Sprague-Dawley rats.

MATERIALS AND METHODS

Animals

National Lacsmi biofarm, Pune, provided healthy female Sprague-Dawley rats weighing 180±10 g the rats were given a regular pellet meal and unlimited water while living in suboptimal settings (22-25ºC, 65-70% humidity, and a 12:12 light/dark cycle). Pravara Rural College of Pharmacy's IAEC accepted the study protocol (CPCSEA Reg. No: 1942/PO/Re/S/17/CPCSEA/2023/01/05/01). Prior to the trial, the animals were acclimated to a 12:12 light/dark cycle for seven days.

Chemicals

Olanzapine was bought in Mumbai, India, from Yarrow Chem Products. 0.1 N hydrochloride acid was used to dissolve olanzapine, 0.1 N NaOH was used to bring the pH down to 5.5 adjust the final volume by using distilled water (Parasuraman et al., 2017).

Preparation of hydroalcholic extract of Caralluma fimbriata

The extract of Caralluma fimbriata was sourced from Green-Chem Herbal Extracts, Bangalore, India. The aerial parts of the plant were collected, shade-dried, and ground. 100 g of the plant material were extracted using 40% aqueous alcohol. The extract was dissolved in distilled water before use (Sudhakara et al., 2014).

Total Phenol Content

The total phenolic content of Caralluma fimbriata extracts was measured using the Folin-Ciocalteu method (Senguttuvan et al., 2014).

Total Flavonoid Content

The total flavonoid content of Caralluma fimbriata extracts was determined using the Dowd method (Dixit et al., 2022).

Study Design

Female SD rats were chosen as the animals, and they were divided into five groups of six using random numbers. The medications were given twice a day for 21 days.

  • NORMAL: Receives Vehicle (0.1 N HCL adjusted pH with 0.1 N NaOH) 2 mL/kg divided in two dose at 12 hr interval,
  • OLZ: Receives olanzapine injected by 2 mg/kg/day, divided in 2 dose at 12 hr interval i.p administration for 21 days Served as control (Kanagali et al., 2022),
  • CFE100+OLZ: Receives olanzapine injected by 2 mg/kg/day, i.p. divided in 2 dose. at 12 hr interval+TCE extract 100 mg/kg one dose orally administration for 21 days,
  • CFE 200+OLZ: Receives olanzapine injected by 2 mg/kg/day, i.p. divided in 2 dose at 12 hr interval+TCE extract 200 mg/kg one dose orally administration for 21 days,
  • CFE 400+OLZ: Receives olanzapine injected by 2 mg/kg/day, i.p. divided in 2 dose at 12 hr interval+CFE extract 400 mg/kg one dose orally administration for 21 days. The animals in each of the five groups' three cages held two each, and they were all fed the same pellet diet.

Measurement of body weight and food intake

Food consumption was monitored daily during the trial. Were measured every day for 24 hr. The following formula was used to determine the food intake for that day in separated metabolic cage place one animal and put feed pellete 5 g after 24 hr remaining food weighed and below formula use for calculation (Ullagaddi et al., 2021).

Measuring % gain body weight

Body weight and food intake were recorded from the first to the twenty-first day. The percentage rise in body weight for the relevant day was calculated using the following formula (Ullagaddi et al., 2021).

Biochemical analysis

Blood was drawn into Eppendorf tubes using the retro-orbital method at the conclusion of the experiment. Samples for following coagulation were centrifuged at 4000 rpm for 5 min at 4ºC. For the purpose of biochemical analysis, the serum was isolated and kept at -20ºC. A glucometer (Accu-Chek Instant, India) was used to measure the levels of glucose. Kits from Trans asia Biomedicals Ltd., AUTOSPAN, and PBHDL these assays were employed to determine Triglycerides (TG), Total Cholesterol (TC), and High-Density Lipoprotein (HDL). Levels of Low-Density Lipoprotein (LDL) and Very-Low-Density Lipoprotein (VLDL) were subsequently calculated were calculated using standard formula (Ullagaddi et al., 2021).

Tissue collection

Weigh an animal's organ. Quickly remove the necessary organ and wash the ice-cold tris buffer twice. Accurately weigh the tissue, then prepare 10% w/v of it with ice-cold tris buffer (10 mM, pH 7.4). Slice the tissue into small pieces, use a homogenizer to create a clear homogeneous mixture, and then place the tissue in a plastic centrifuge set on high speed cooling (6000 rpm for 20 min). Maintain the homogenate in a frozen state.

In liver tissue measuring the amount of Malondialdehyde (MDA)

Malondialdehyde (MDA) levels in liver tissue were measured using the Thiobarbituric Acid (TBA) reaction. 200 mg of liver samples were homogenized in 1.15% KCl to create a 10% tissue homogenate. 500 µL of this homogenate were mixed with 3 mL of 1% phosphoric acid and 1 mL of 0.6% TBA. The combination was heated for 45 min in boiling water, then cooled and vortexes with 4 mL of butanol. After 15 to 20 min of centrifugation the top pink layer was seen at 532 nm. The MDA content of the tissue was expressed as nmol/g (Kumar et al., 2012).

In liver tissue measuring the amount of Glutathione (GSH)

The assay is based on the interaction of sulfhydryl groups with 5, 5'-dithiobis-(2-nitrobenzoic acid) (DTNB), producing a yellow-colored compound that exhibits maximum absorbance at 412 nm. For the procedure, 200 mg of liver tissue was homogenized in phosphate buffer (pH 7.4) to obtain a 10% homogenate. A 500 µL aliquot of this homogenate was mixed with 500 µL of 10% Trichloroacetic Acid (TCA) and centrifuged at 10,000 rpm for 6 min. Subsequently, 500 µL of the resulting supernatant was added to 2.5 mL of phosphate buffer (pH 8) and 500 µL of DTNB solution. Absorbance was recorded at 412 nm, and reduced Glutathione (GSH) concentration was determined from a standard calibration curve (Mihara et al., 1978).

In liver tissue measuring the amount of Catalase (CAT) in liver tissue

Catalase activity was assessed by mixing 50 μL of tissue supernatant with 1.0 mL of 50 mm phosphate buffer (pH 7) and 0.1 mL of 30 mm hydrogen peroxide. The change in absorbance was monitored at 240 nm for 30 sec at 5 sec intervals, and the rate of decrease was used to calculate enzyme activity. Results were expressed as units (U) per gram of tissue (Ellman et al., 1959).

Measuring the amount of Superoxide Dismutase (SOD) in liver tissue

640 μL of distilled water, 10 μL of 0.3% Triton X-100, 100 μL of 1 mm EDTA, 100 μL of 240 μm NBT, 25 μL of tissue supernatant, and 1 mm hydroxylamine were mixed to create a mixture for the enzyme activity test. To track the increase in the reaction's slope, spectrophotometric measurements were taken in kinetic mode for 3 min at a wavelength of 560 nm at 1 min intervals. The enzyme activity was measured in units (U) per gram of tissue (Aebi et al., 1984).

Histopathological Studies

Liver tissues removal was done from euthanized animals and immediately fixed using 10% neutral buffered formalin (pH 7.4±0.2) at room temperature (25±2ºC) for 48 hr (Mark et al., 2007, Zeng et al., 2023).

Statistical analysis

All of the data are analyzed using GraphPad Prism version 10, the results are displayed as Mean±SEM. Body weight, food and water intake, blood glucose levels during the OGTT, and locomotor activity were all investigated using two-way ANOVA and Tukey's post hoc test. Mean±SEM is used to show oxidative stress in addition to the lipid profile. One-way ANOVA using GraphPad Prism software (version 10) and Bonferroni post hoc tests.

RESULTS

Effect on body weight

Olanzapine-treated rats showed significant weight gain (p<0.0001) vs. Normal rats. Co- administration of CFE (100, 200, 400 mg/kg) with Olanzapine significantly reduced weight gain (p<0.001) from day 6 to 21 (Table 1).

Effect on cumulative food intake

Co-administration of CFE (200, 400 mg/kg) with Olanzapine (2 mg/kg) significantly decreased cumulative food intake (p<0.0001) from day 6 to 21. Olanzapine-treated rats showed increased cumulative food intake (p<0.0001) compared to Normal rats on day 21 (Table 2).

Effect of CFE on lipid profile

Significant alterations were detected in the lipid profile parameters-Triglycerides (TG), Total Cholesterol (TC), High-Density Lipoprotein (HDL), Low-Density Lipoprotein (LDL), and Very-Low-Density Lipoprotein (VLDL)-among the study groups (p<0.0001). Administration of olanzapine resulted in marked increases in TG, TC, LDL, and VLDL levels (all p<0.0001), accompanied by a significant reduction in HDL concentration (p<0.0001). Co-treatment with Caralluma fimbriata extract (CFE) at 200 and 400 mg/kg effectively mitigated olanzapine-induced dyslipidemia, as shown by elevated HDL levels (p<0.01) and reduced TG (p<0.001) and VLDL (p<0.001) values. In addition, supplementation with CFE at 100, 200, and 400 mg/kg produced a significant decline in LDL (p<0.0001) and TC (p<0.001) compared with olanzapine alone (Table 3).

Effect on organ weight

A notable variation in the weight of the organs was noted. When CFE (100,200,400 mg/kg) and olanzapine were administered together, there was a substantial decrease in the weight of the liver (p<0.0001), heart (p<0.05) and adipose tissue when compared to rats treated with olanzapine. However, as compared to the olanzapine group, there was no discernible difference in kidney weight. Compared to the typical and non-significant difference in heart and kidney weight, the olanzapine-treated group had significantly greater liver and adipose tissue organ weight (Table 4).

Effect of on MDA, GSH, CAT and SOD levels of liver tissue

Catalase (CAT) Olanzapine treatment showed non-significant changes in liver CAT levels compared to Normal group. Co-administration of CFE (100-400 mg/kg) with olanzapine also showed non-significant changes in CAT levels. Malondialdehyde (MDA) Olanzapine treatment significantly increased MDA levels in liver tissue (p<0.05) compared to Normal group. Co-administration of CFE (100-400 mg/kg) with olanzapine significantly decreased MDA levels (p<0.01). Superoxide Dismutase (SOD) Olanzapine treatment significantly decreased SOD levels in liver tissue compared to Normal group. Co-administration of CFE (100-400 mg/kg) with olanzapine significantly increased SOD levels (Table 5).

Effect of Olanzapine and co- administration of CFE (100, 200, 300 mg/kg) plus OLZ (2 mg/kg) on Liver Histopathology alterations in female SD rat

Hematoxylin and eosin-stained sections of liver tissues collected. H and E staining was used to determine various changes viz. Abnormalities of liver cells and Necrosis of hepatic cells (Magnification: 10X and 40X). Microscopic examination of liver sample from Normal group did not show any abnormality of pathologic al significance. Assessment of liver sample from OLZ group showed Hepatic cell with ballooning degeneration, focal necrotic cell death and diffuse changes. Abnormality was detected in liver tissues. CFE100, CFE200, CFE400 with OLZ groups show Normal hepatocytes arranged, with obvious sinusoids, and central vein no abnormality detected. The severity and incidence rate of these changes was reduced after treatment with CFE 100, CFE200, CFE 400 Plus OLZ (Figure 1).

Table 1: Body weight gain (%) at different interval (Days) in rat treated with vehicle olanzapine (2 mg/kg) Olanzapine+CFE (100, 200, 400 mg/kg/day).
Group/DaysMean±SEM
Days 36912151821
Normal0.097±0.0971.262±0.0982.628±0.2014.077±0.2655.567±0.3376.723±0.3338.183±0.348
Olanzapine1.065±0.1823.372±0.3086.847±0.2739.942±0.322 ****14.315±0.785 ****16.98±0.414 ****19.495±0.214 ****
CFE100+ OLZ1.754±0.5013.703±1.4148.284±1.1838.382±1.39810.623±1.371 #132.1±1.967 #12.9±2.650 ####
CFE200+ OLZ1.744±0.3972.186±0.6162.519±0.715 ##3.294±1.160 ####5.038±0.789 ####4.554±0.726 ####7.267±0.469 ####
CFE400+ OLZ0.821±0.2401.259±0.4611.065±0.277 ##1.550±0.746 ####1.550±0.649 ####1.258±0.460 ####1.555±0.653 ####
Table 2: Cumulative Feed intake at Different Interval (Days) rat treated with vehicle olanzapine (2mg/kg) Olanzapine+CFE (100, 200, 400 mg/kg/day).
Group/ DaysMean±SEM
36912151821
Normal64.633 ±2.331119.910 ±5.535170.437 ±6.789230.17 ±5.916286.407 ±8.353353.623 ±7.576407.487 ±11.508
Olanzapine48.887 ±1.226104.717 ±3.515172.267±3.564241.37 ±3.010301.013 ±2.764371.073 ±3.378444.357 ±3.588 ****
CFE100+ OLZ51.167 ±1.216107.667 ±2.348162.883±2.348216.833 ±2710 #265.000 ±2.834 ###309.000 ±3.286 ####361.500 ±4.427 ####
CFE200+ OLZ29.487 ±0.42356.653 ±1.979 ####85.930±3.298 ####115.917 ±2.682 ####148.223 ±3.222 ####181.517 ±3.881 ####214.597 ±4.421 ####
CFE400+ OLZ28.500 ±2.28856.667 ±4.228 ####84.500±7.526 ####114.667 ±10.016 ####150.330 ±10.016 ####188.350 ±9.923 ####220.433 ±12.835 ####
Table 3: Lipid profile in rats treated with vehicle olanzapine (2 mg/kg/day), olanzapine plus CFE (100,200,400 mg/kg/day).
GroupsTC (mg/dL)TG (mg/dL)HDL (mg/dL)LDL (mg/dL)VLDL (mg/dL)
Normal46.21±1.50040.58±1.82741.78±0.56138.117±0.36488.117±0.3648
Olanzapine62.61±0.9840 ****88.19±3.432 **25.32±1.126 ****17.64±0.6866 *17.64±0.6866 *
CFE100+OLZ63.27±0.9855108.7±13.6222.36±2.23620.01±3.84321.74±2.724
CFE200+OLZ46.42±1.288 ####53.21±5.873 #22.28±2.25413.50±2.2687.773±3.457 #
CFE400+OLZ30.57±1.078 ####52.33±1.144 #27.88±2.012-7.775±1.49510.47±0.2297 ####
Table 4: Organ weight rats treated with vehicle olanzapine (2 mg/kg/day), OLZ plus TCE (100, 200, 400 mg/kg/day). Plus CFE (100, 200, 400 mg/kg/day).
GROUPSHeart(gm.)Adipose tissue (gm)Kidney (gm)Liver (gm)
NORMAL0.61±0.035.03±0.220.64±0.016.31±0.25
OLZ0.67±0.038.14±0.38 ****0.76±0.057.44±0.12 **
CFE100+OLZ0.58±0.015.15±0.26 ####0.68±0.026.60±0.25
CFE200+OLZ0.59±0.024.23±0.18 ####0.63±0.005.74±0.18 ####
CFE400+OLZ0.52±0.02 #3.75±0.42 ####0.61±0.015.55±0.19 ####
Table 5: Oxidative stress in rats treated with vehicle Olanzapine (2 mg/kg/day), Olanzapine+CFE (100, 200, 400 mg/kg/day).
GroupsCAT (micromole of H2O2/gm of tissue)GSH (micromole of H2O2/gm of tissue)MDA (micromole of H2O2/gm of tissue)SOD (unit/gm of tissue)
Normal7.960±0.14361275±75.9528.62±3.0110.3283±0.07631
Olanzapine7.717±0.0076824.5±18.34 ***53.54±6.402 **0.5750±0.07513 **
CFE100+OLZ7.723±0.0968844.0±22.0927.77±2.034 ##0.7550±0.03394 ##
CFE200+OLZ7.757±0.2780880.5±16.8537.94±6.14005633±0.04821
CFE400+OLZ7.928±0.1712911.5±27.5233.28±2.4250.4733±0.1094
Figure 1: Effect in rats treated with vehicle olanzapine (2 mg/kg/day),OLZ plus CFE (100,200,400 mg/kg/day) on liver histopathological changes in SD rat. Hematoxylin and eosin-stained sections of liver tissues collected. Hand E-staining was used to determine various changes viz. Abnormalities of liver cells and Necrosis of hepatic cells (Magnification: 10X and 40X). Microscopic Examination of Liver Sample From Normal group not show any abnormality of pathological significance. Assessment of liver sample from OLZ groups showed Hepatic cell with ballooning degeneration, focal necrotic cell death and diffuse changes. Abnormality was detected in liver tissues. CFE100, CFE200, CFE400 with OLZ groups show normal hepatocytes arranged, with obvious sinusoids, and central vein no abnormality detected. The severity and incidence rate of the changes was reduced after treatment with CFE100, CFE200, CFE400 plus OLZ.

DISCUSSION

The present study aimed to investigate the potential therapeutic effects of Caralluma fimbriata extract (CFE) in mitigating the metabolic and biochemical alterations induced by olanzapine, a commonly prescribed atypical antipsychotic. Olanzapine, while effective for treating psychiatric disorders, is known to induce a range of metabolic side effects including weight gain, dyslipidemia, and increased oxidative stress. The results of the present study provide promising evidence that CFE may serve as an adjunctive therapy to counteract these adverse effects.

The administration of olanzapine (2 mg/kg/day) for 21 days resulted in a significant increase in body weight, which is consistent with previous reports of olanzapine-induced hyperphagia and weight gain in animal models (Gujjala et al., 2016, Ferno et al., 2011). In the current study, CFE administration (100, 200, and 400 mg/kg) significantly reduced body weight gain in olanzapine-treated rats. Notably the highest dose (400 mg/kg) exhibited the most pronounced effect which aligns with findings from prior studies showing CFE’s potential as an appetite-suppressant and anti-obesity agent (Sudhakara et al., 2014). The dose-dependent reduction in food intake observed in the CFE-treated rats suggests that CFE may help regulate appetite and improve metabolic balance, likely through its bioactive compounds.

Olanzapine administration led to significant alterations in lipid metabolism, including increased Triglycerides (TG), Low-Density Lipoprotein (LDL), Very-Low-Density Lipoprotein (VLDL) and Total Cholesterol (TC) alongside a reduction in High-Density Lipoprotein (HDL). These dyslipidemia effects have been widely documented in literature as part of the metabolic syndrome associated with olanzapine use (Gujjala et al., 2016, Ferno et al., 2011). The co-administration of CFE significantly mitigated these lipid disturbances. At doses of 200 and 400 mg/kg, CFE reduced the levels of TG, VLDL, LDL, and TC while increasing HDL. These findings suggest that CFE may enhance lipid metabolism and have lipid-lowering effects, as previously observed in studies where CFE improved lipid profiles in high-fat diet-induced models (Gujjala et al., 2017). The underlying mechanisms may involve modulation of lipid-regulating enzymes and antioxidant pathways, which warrants further exploration.

Olanzapine treatment led to increased liver and adipose tissue weights, indicative of lipid accumulation and potential hepatotoxicity. This is consistent with reports of olanzapine-induced hepatic damage and fat deposition in various tissues (Gujjala et al., 2016). However, co administration of CFE (100-400 mg/kg) significantly reduced both liver and adipose tissue weights, particularly at the highest dose. This suggests that CFE may have hepatoprotective effects and could prevent fat accumulation in adipose tissue, as demonstrated by its impact on hepatic lipid levels and structural integrity in previous studies (Gujjala et al., 2016). These observations further support the potential of CFE as a therapeutic agent for managing olanzapine-induced metabolic disturbances.

Oxidative stress plays a crucial role in the pathogenesis of olanzapine-induced metabolic syndrome (Ardakanian A et al., 2022). In the current study olanzapine treatment increased Malondialdehyde (MDA) levels, a marker of lipid peroxidation, and decreased Superoxide Dismutase (SOD) activity, an important antioxidant enzyme. These findings corroborate the oxidative damage observed in olanzapine-treated animals (Gujjala et al., 2016, Ferno et al., 2011). Co-administration of CFE significantly reduced MDA levels and increased SOD activity, demonstrating its antioxidant potential. The antioxidant effects of CFE may contribute to its protective role in mitigating oxidative damage and preventing the development of metabolic syndrome. Similar antioxidant properties of CFE have been observed in high-fat diet-induced models of oxidative stress (Ardakanian et al., 2022). Histopathological examination of liver tissue revealed severe alterations in the hepatic architecture of olanzapine-treated rats, including ballooning degeneration, necrosis, and widespread cell death. These findings are in line with previous reports of hepatotoxicity associated with antipsychotic medications (Gujjala et al., 2016). In contrast, rats co-treated with CFE exhibited preserved liver architecture, with less extensive tissue damage. These histopathological findings suggest that CFE may exert hepatoprotective effects, which could be attributed to its antioxidant properties and its ability to modulate lipid metabolism.

CONCLUSION

In conclusion, the results of the present study provide compelling evidence that Caralluma fimbriata extract (CFE) may effectively alleviate olanzapine-induced metabolic side effects, including weight gain, dyslipidemia, oxidative stress, and hepatotoxicity. The appetite-suppressing, lipid-lowering, and antioxidant properties of CFE suggest that it could be a valuable adjunctive therapy for managing olanzapine-induced metabolic syndrome. However, while these findings are promising, further clinical studies are required to validate these effects in humans and elucidate the precise molecular mechanisms through which CFE exerts its therapeutic actions. Additionally, future research should explore the interactions between CFE’s secondary metabolites and the molecular targets involved in the regulation of metabolism and oxidative stress in the context of olanzapine-induced metabolic disturbances.

Acknowledgement

I express my deep gratitude to the Department of Pharmacology, Pravara Rural College of Pharmacy, for providing me with the facilities and support required to carry out this research successfully.

I am profoundly thankful to my guide, Dr. B.M. Patil, for his invaluable guidance, encouragement, and constant support throughout the course of this research work. His expertise and insightful suggestions have been instrumental in shaping this study.

Conflict of Interest

The authors declare that there is no conflict of interest.

Ethics Statement

The study adhered to ethical guidelines as approved by the Institutional Animal Ethics Committee (IAEC) of Pravara Rural College of Pharmacy. The animals were provided with standard care conditions, including a regular diet and proper housing environment. All experimental procedures were conducted in compliance with CPCSEA regulations to ensure humane treatment of the animals throughout the research process.

REFERENCES

As published

Showing references and in-text citations exactly as published.

  1. Aebi, H. (1984). Catalase in vitro. Methods in Enzymology, 105, 121–126. )05016-3. https://doi.org/10.1016/s0076-6879(84CrossrefGOOGLE SCHOLAR
  2. Ansari, M. A, Shukla, A. K, Oves, M, Khan, H. M, & Musarrat, J. (2016). Electron microscopic ultrastructural study on the toxicological effects of AgNPs on the liver, kidney, and spleen tissues of albino mice. Environmental Toxicology and Pharmacology, 44, 30–43. https://doi.org/10.1016/j.etap.2016.04.007CrossrefGOOGLE SCHOLAR
  3. Ardakanian, A, Rahbardar, G, M, Omidkhoda, F, Razavi, B. M, & Hosseinzadeh, H. (2022). Effect of alpha-mangostin on olanzapine-induced metabolic disorders in rats. Iranian Journal of Basic Medical Sciences, 25(2), 198–207. https://doi.org/10.22038/IJBMS.2022.58734.13047CrossrefGOOGLE SCHOLAR
  4. Astell, K. J, Mathai, M. L, McAinch, A. J, Stathis, C. G, & Su, X. Q. (2013). A pilot study investigating the effect of caralluma fimbriata extract on the risk factors of metabolic syndrome in overweight and obese subjects: A randomised controlled clinical trial. Complementary Therapies in Medicine, 21(3), 180–189. https://doi.org/10.1016/j.ctim.2013.01.004CrossrefGOOGLE SCHOLAR
  5. Deng, C, Lian, J, Pai, N, & Huang, X. (2012). Reducing olanzapine-induced weight gain side effect by using Betahistine: A study in the rat model. Journal of Psychopharmacology, 26(9), 1271–1279. https://doi.org/10.1177/0269881112449396CrossrefGOOGLE SCHOLAR
  6. Dixit, M. P, Sammeta, S. S, Dhokne, M. D, Mangrulkar, S, Upadhya, M. A, Umekar, M. J, Taksande, B. G, & Kotagale, N. R. (2022). Chronic agmatine treatment prevents olanzapine-induced obesity and metabolicdysregulation in female rats. Brain Research Bulletin, 191, 69–77. https://doi.org/10.1016/j.brainresbull.2022.10.013CrossrefGOOGLE SCHOLAR
  7. Ellman, G. L. (1959). Tissue sulfhydryl groups. Archives of Biochemistry and Biophysics, 82(1), 70–77. )90090-6. https://doi.org/10.1016/0003-9861(59CrossrefGOOGLE SCHOLAR
  8. Fernø, J, Varela, L, Skrede, S, Vázquez, M. J, Nogueiras, R, Diéguez, C, Vidal-Puig, A, Steen, V. M, & López, M. (2011). Olanzapine-induced hyperphagia and weight gain associate with orexigenic hypothalamic neuropeptide signaling without concomitant AMPK phosphorylation. PLOS One, 6(6), Article E20571. https://doi.org/10.1371/journal.pone.0020571CrossrefGOOGLE SCHOLAR
  9. Gujjala, S, & Sudhakara, G. (2017). Modulatory effects of caralluma fimbriata extract against high-fat diet-induced abnormalities in carbohydrate metabolism in wistar rats. Biomedicine and Pharmacotherapy, 92, 1062–1072. https://doi.org/10.1016/j.biopha.2017.06.016CrossrefGOOGLE SCHOLAR
  10. Gujjala, S, Putakala, M, Ramaswamy, R, & Desireddy, S. (2016). Preventive effect of caralluma fimbriata vs. Metformin Against High-fat Diet-induced Alterations in Lipid Metabolism in Wistar Rats. Biomedicine and Pharmacotherapy, 84, 215–223. https://doi.org/10.1016/j.biopha.2016.09.029CrossrefGOOGLE SCHOLAR
  11. Gupta, R. K, Hussain, T, Panigrahi, G, Das, A, Singh, G. N, Sweety, K, Faiyazuddin, M, & Rao, C. V. (2011). Hepatoprotective effect of solanumxanthocarpum fruit extract against CCl. Asian Pacific Journal of Tropical Medicine, 4(12), 964–968. )60227-7. https://doi.org/10.1016/S1995-7645(11CrossrefGOOGLE SCHOLAR
  12. Hardy, T. A, Henry, R. R, Forrester, T. D, Kryzhanovskaya, L. A, Campbell, G. M, Marks, D. M, & Mudaliar, S. (2011). Impact of olanzapine or risperidone treatment on insulin sensitivity in schizophrenia or schizoaffective disorder. Diabetes, Obesity and Metabolism, 13(8), 726–735. https://doi.org/10.1111/j.1463-1326.2011.01398.xCrossrefGOOGLE SCHOLAR
  13. Huhn, M, Nikolakopoulou, A, Schneider-Thoma, J, Krause, M, Samara, M, Peter, N, Arndt, T, Bäckers, L, Rothe, P, Cipriani, A, Davis, J, Salanti, G, & Leucht, S. (2019). Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: A systematic review and network meta-analysis. The Lancet, 394(10202), 939–951. )31135-3. https://doi.org/10.1016/S0140-6736(19CrossrefGOOGLE SCHOLAR
  14. Kamalakkannan, S, Rajendran, R, Venkatesh, R. V, Clayton, P, & Akbarsha, M. A. (2010). Antiobesogenic and antiatherosclerotic properties of caralluma fimbriata extract. Journal of Nutrition and Metabolism, Article 285301. https://doi.org/10.1155/2010/285301CrossrefGOOGLE SCHOLAR
  15. Kanagali, S. N, Patil, B. M, Khanal, P, & Unger, B. S. (2022). Cyperus rotundus L. Reverses the Olanzapine-induced Weight Gain and Metabolic Changes Outcomes From Network and Experimental Pharmacology. Computers in Biology and Medicine, 141, Article 105035. https://doi.org/10.1016/j.compbiomed.2021.105035CrossrefGOOGLE SCHOLAR
  16. Karunakaran, S. (2020). Unraveling early signs of navigational impairment in APPswe/PS1dE9 mice using morris water maze. Frontiers in Neuroscience, 14, Article 568200. https://doi.org/10.3389/fnins.2020.568200CrossrefGOOGLE SCHOLAR
  17. Kumar, R, Patel, D, Prasad, S, Sairam, K, & Hemalatha, S. (2012). Antidiabetic activity of alcoholic root extract of caesalpinia digyna in streptozotocin-nicotinamide induced diabetic rats. Asian Pacific Journal of Tropical Biomedicine, 2(2), S934-s940. )60340-, 2. https://doi.org/10.1016/S2221-1691(12CrossrefGOOGLE SCHOLAR
  18. Lanktree, M. B. (2018). Genomic and precision medicine: Metabolic syndrome, 47-63. https://doi.org/10.1016/B978-0-12-801812-5.00015-9CrossrefGOOGLE SCHOLAR
  19. Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, Lobos, A, C, Schwarz, S, & Davis, J. M. (2009). A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. The American Journal of Psychiatry, 166(2), 152–163. https://doi.org/10.1176/appi.ajp.2008.08030368CrossrefGOOGLE SCHOLAR
  20. Lin, C, Lin, S, Huang, Y, Wang, F, & Huang, C. (2018). Early prediction of olanzapine-induced weight gain for schizophrenia patients. Psychiatry Research, 263, 207–211. https://doi.org/10.1016/j.psychres.2018.02.058CrossrefGOOGLE SCHOLAR
  21. Mark, M, Teletin, M, Antal, C, Wendling, O, Auwerx, J, Heikkinen, S, Khetchoumian, K, Argmann, C. A, & Dgheem, M. (2007). Histopathology in mouse metabolic investigations. Current Protocols in Molecular Biology. https://doi.org/10.1002/0471142727.mb29b04s78CrossrefGOOGLE SCHOLAR
  22. Meftah, A. M, Deckler, E, Citrome, L, & Kantrowitz, J. T. (2020). New discoveries for an old drug: A review of recent olanzapine research. Postgraduate Medicine, 132(1), 80–90. https://doi.org/10.1080/00325481.2019.1701823CrossrefGOOGLE SCHOLAR
  23. Mihara, M, & Uchiyama, M. (1978). Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Analytical Biochemistry, 86(1), 271–278. )90342-1. https://doi.org/10.1016/0003-2697(78CrossrefGOOGLE SCHOLAR
  24. Parasuraman, S, Zhen, K. M, Banik, U, & Christapher, P. V. (2017). Ameliorative effect of curcumin on olanzapine-induced obesity in Sprague-Dawley rats. Pharmacognosy Research, 9(3), 247–252. https://doi.org/10.4103/pr.pr_8_17CrossrefGOOGLE SCHOLAR
  25. Sayed, E, H, E. S. A, Morsy, L. E. S, Emara, A, T, M, & Galhom, R. A. (2019). Effect of carbon tetrachloride (CCl₄) on liver in adult albino rats: Histological study. The Egyptian Journal of Hospital Medicine, 76(6), 4254–4261. https://doi.org/10.21608/ejhm.2019.43804CrossrefGOOGLE SCHOLAR
  26. Senguttuvan, J, Paulsamy, S, & Karthika, K. (2014). Phytochemical analysis and evaluation of leaf and root parts of the medicinal herb, hypochaeris radicata L. For in Vitro Antioxidant Activities. Asian Pacific Journal of Tropical Biomedicine, 4(suppl. 1), S359-s367. https://doi.org/10.12980/APJTB.4.2014C1030CrossrefGOOGLE SCHOLAR
  27. Sudhakara, G, Mallaiah, P, Sreenivasulu, N, Rao, S. B, B, Rajendran, R, & Saralakumari, D. (2014). Beneficial effects of hydro-alcoholic extract of caralluma fimbriata against high-fat diet-induced insulin resistance and oxidative stress in wistar male rats. Journal of Physiology and Biochemistry, 70(2), 311–320. https://doi.org/10.1007/s13105-013-0304-1CrossrefGOOGLE SCHOLAR
  28. Svensson, C. K, Larsen, J. R, Vedtofte, L, Jakobsen, M. S. L, Jespersen, H. R, Jakobsen, M. I, Koyuncu, K, Schjerning, O, Nielsen, J, Ekstrøm, C. T, Correll, C. U, Vilsbøll, T, & Fink-Jensen, A. (2019). One-year follow-up on liraglutide treatment for prediabetes and overweight/obesity in clozapine- Or olanzapine-treated patients. Acta Psychiatrica Scandinavica, 139(1), 26–36. https://doi.org/10.1111/acps.12982CrossrefGOOGLE SCHOLAR
  29. Thomas, K, & Saadabadi, A. (2023). Olanzapine. Statpearls. https://www.ncbi.nlm.nih.gov/books/NBK532903/GOOGLE SCHOLAR
  30. Ullagaddi, M. B, Patil, B. M, & Khanal, P. (2021). Beneficial effect of zingiber officinale on olanzapine-induced weight gain and metabolic changes. Journal of Diabetes and Metabolic Disorders, 20(1), 41–48. https://doi.org/10.1007/s40200-020-00695-xCrossrefGOOGLE SCHOLAR
  31. Zeng, J, Acin-Perez, R, Assali, E. A, Martin, A, Brownstein, A. J, Petcherski, A, Fernández-Del-Rio, L, Xiao, R, Lo, C. H, Shum, M, Liesa, M, Han, X, Shirihai, O. S, & Grinstaff, M. W. (2023). Restoration of lysosomal acidification rescues autophagy and metabolic dysfunction in non-alcoholic fatty liver disease. Nature Communications, 14(1), 2573. https://doi.org/10.1038/s41467-023-38165-6CrossrefGOOGLE SCHOLAR

Cite this article

SELECT FORMAT

Bhausaheb, D. S., Shantaram, J. S., Balasaheb, B. S., Dadasaheb, G. R., Aniket, P. V., & Santosh, P. S. (2025). Effect of Caralluma fimbriata Hydroalcoholic Extraction on Olanzapine-Induced Hyperphagia and Metabolic Changes in Rats. Journal of Young Pharmacists, 17(4), 914-921. https://doi.org/10.5530/jyp.20250150

Copyright and licence

© 2025 Author(s)

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms. CC BY-NC-SA 4.0